Off-Label Use of Drug-Eluting Stents. Putting it in Perspective**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 51, Issue 6, 2008, Pages 615-617

  Grines, Cindy L ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARE METAL STENT; DRUG ELUTING STENT; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; STENT; STENT THROMBOSIS; THROMBOSIS; TREATMENT INDICATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DEVICE APPROVAL; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 38749092241     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.10.028     Document Type: Editorial

References (28)

1. Boston Scientific Corp. Form 10-Q. Item 2. Management's discussion and analysis of financial condition and results of operations. Quarterly report; Aug 8, 2007. http://biz.yahoo.com/e/070808/bsx10-q.html Accessed September 7, 2007
2. Stent News. Problems resurface with drug-eluting stents. http://www.ptca.org/news/2006/0904.html Accessed September 7, 2007
3. Kirk H. Drug eluting stent problems lead to share fall in sales last year. http://www.youhavealawyer.com/blog/2007/08/09 Accessed September 7, 2007
4. Food and Drug Administration (FDA). Update to FDA statement on coronary drug-eluting stents. http://www.fda.gov/cdrh/news/010407.html Accessed September 7, 2007
5. Food and Drug Administration (FDA). Theory, evidence and examples of FDA harm. http://www.fdareview.org/harm.shtml Accessed September 7, 2007
6. Russell M.E., Friedman M.I., Mascioli S.R., and Stolz L.E. Off-label use: an industry perspective on expanding use beyond approved indications. J Interv Cardiol 19 (2006) 432-438
7. Holmes Jr. D.R., Bell M.R., Holmes III D.R., et al. Interventional cardiology and intracoronary stents-a changing practice: approved vs. nonappproved indications. Cathet Cardiovasc Diagn 40 (1997) 133-138
8. Food and Drug Administration (FDA). "Off-label" and investigational use of marketed drugs, biologics, and medical devices. Guidance of institutional review boards and clinical investigators. 1998. http://www.fda.gov/oc/ohrt/irbs/offlabel.html Accessed September 7, 2007
9. Beohar N., Davidson C.J., Kip K.E., et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297 (2007) 1992-2000
10. Win H.K., Caldera A.E., Maresh K., et al., EVENT Registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (2007) 2001-2009
11. Rao S.V., Shaw R.E., Brindis R.G., Klein L.W., Weintraub W.S., and Peterson E.D. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol 97 (2006) 1478-1481
12. Applegate R.J., Sacrinty M.T., Kutcher M.A., et al. "Off-label" stent therapy: 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol 51 (2008) 607-614
13. O'Neill W.W., Dixon S.R., and Grines C.L. The year in interventional cardiology. J Am Coll Cardiol 45 (2005) 1117-1134
14. Dixon S.R., Grines C.L., and O'Neill W.W. The year in interventional cardiology. J Am Coll Cardiol 47 (2006) 1689-1706
15. Kelbaek H., Thuesen L., Helqvist S., et al. The Stenting Coronary Arteries in Non-stress/Benestent Disease (SCANDSTENT) trial. J Am Coll Cardiol 47 (2006) 449-455
16. Kereiakes D.J., Wang H., Popma J.J., et al. Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents. J Am Coll Cardiol 48 (2006) 21-31
17. Alfonso F., Perez-Vizcayno M.J., Hernandez R., et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol 47 (2006) 2152-2160
18. Stone G.W., Ellis S.G., O'Shaughnessy C.D., et al. Paclitaxel-eluting stents vs. vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 295: (2006) 1253-1263
19. Dibra A., Kastrati A., Alfonso F., et al. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis. J Am Coll Cardiol 49 (2007) 616-623
20. Vermeersch P., Agostoni P., Verheye S., et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts. J Am Coll Cardiol 48 (2006) 2423-2431
21. Suttorp M.J., Laarman G.J., Rahel B.M., et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 114 (2006) 921-928
22. Kastrati A., Dibra A., Spaulding C., et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 28 (2007) 2706-2713
23. Lagerqvist B., James S.K., Stenestrand U., et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
24. James S. New Swedish registry results show no overall increased deaths with DES out to four years. http://www.theheart.org Accessed September 3, 2007
25. Tu J.V., Bowen J., Chiu M., et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 357 (2007) 1393-1402
26. Jensen L.O., Maeng M., Kaltoft A., et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 50 (2007) 463-470
27. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
28. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. J Am Coll Cardiol 49 (2007) 734-739